Compare Novavax Inc (NVAX) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Toro Company (The) Common Stock — how do they compare? Novavax Inc trades at $12.46 (market cap $2.11B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Toro Company (The) Common Stock is far larger — about 4.4× Novavax Inc's market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Toro Company (The) Common Stock for 0 Days on average.
| NVAX | TTC | |
|---|---|---|
Market Cap | $2.11B | $9.27B |
Volume | 8,376,831 | 688,325 |
Sector | Health | Industrials |
52-Week High | $12.82 | $101.76 |
52-Week Low | $6.22 | $67.99 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.69B | $10.17B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.64, down slightly by 0.16% on the day. The stock shows a bullish technical signal with strong moving average and oscillator support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of -$0.32 surpassing the -$0.38 estimate. The company is transitioning its business model toward a partnership-driven approach centered on its Matrix-M adjuvant technology, with recent regulatory approvals for its updated COVID-19 vaccine in major markets.
The outlook is mixed with strong analyst buy ratings (73.9%) and recent business developments providing catalysts, but significant financial risks remain including negative cash flows, high debt levels, and inconsistent profitability. Investment opportunity exists in the partnership strategy execution, while risks include execution challenges and competitive pressures in the vaccine market.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
